Lee's Pharmaceutical Holdings Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
1,137
- Stock Symbol
-
00950
- Investments
-
7
- Share Price
-
$0.13
- (As of Friday Closing)
Lee's Pharmaceutical Holdings General Information
Description
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
Contact Information
Website
www.leespharm.comCorporate Office
- 1/F, Building 20E, Phase 3
- Hong Kong Science Park
- Hong Kong
- Hong Kong
Corporate Office
- 1/F, Building 20E, Phase 3
- Hong Kong Science Park
- Hong Kong
- Hong Kong
Lee's Pharmaceutical Holdings Stock Performance
As of 13-Nov-2026, Lee's Pharmaceutical Holdings’s stock price is $0.13. Its current market cap is $78.8M with 589M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.13 | $0.13 | $0.13 - $0.24 | $78.8M | 589M | 555K | $0.03 |
Lee's Pharmaceutical Holdings Financials Summary
As of 30-Jun-2026, Lee's Pharmaceutical Holdings has a trailing 12-month revenue of $197M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 53,731 | 91,132 | 103,344 | 110,623 |
| Revenue | 196,837 | 184,187 | 179,408 | 134,501 |
| EBITDA | 13,178 | 30,476 | 33,003 | 24,272 |
| Net Income | 15,331 | 11,793 | 11,931 | 2,133 |
| Total Assets | 444,099 | 445,143 | 337,202 | 369,920 |
| Total Debt | 31,864 | 39,873 | 29,278 | 26,124 |
Lee's Pharmaceutical Holdings Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lee's Pharmaceutical Holdings Signals
Lee's Pharmaceutical Holdings Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lee's Pharmaceutical Holdings Investments & Acquisitions (7)
Lee's Pharmaceutical Holdings’s most recent deal was a Merger/Acquisition with Alexza Pharmaceuticals (Staccato One Breath Platform Technology). The deal was made on 13-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Alexza Pharmaceuticals (Staccato One Breath Platform Technology) | 13-Dec-2025 | Merger/Acquisition | Drug Delivery | ||
| Aimwell Partners | 16-Feb-2023 | Reverse Merger | Automotive | ||
| Zhaoke Ophthalmology | 30-Oct-2020 | Early Stage VC | Pharmaceuticals | ||
| Windtree Therapeutics | 04-Apr-2018 | PIPE | Biotechnology | ||
| Dilafor | 27-Sep-2016 | Later Stage VC | Drug Discovery |
Lee's Pharmaceutical Holdings ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Lee's Pharmaceutical Holdings Exits (4)
Lee's Pharmaceutical Holdings’s most recent exit was on 30-Oct-2020 from Zhaoke Ophthalmology. The exit was categorized as with 13 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Zhaoke Ophthalmology | 30-Oct-2020 | Completed |
|
||
| Windtree Therapeutics | 04-Apr-2018 | Completed |
|
||
| FiberSense (Monitoring Equipment) | 27-Nov-2014 | Completed |
|
||
| CVie Therapeutics Company | 07-Aug-2012 | Joint Venture | Completed |
Lee's Pharmaceutical Holdings Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| CVie Therapeutics Company | Taipei, Taiwan | 2012 |
Lee's Pharmaceutical Holdings FAQs
-
When was Lee's Pharmaceutical Holdings founded?
Lee's Pharmaceutical Holdings was founded in 1994.
-
Where is Lee's Pharmaceutical Holdings headquartered?
Lee's Pharmaceutical Holdings is headquartered in Hong Kong, Hong Kong.
-
What is the size of Lee's Pharmaceutical Holdings?
Lee's Pharmaceutical Holdings has 1,137 total employees.
-
What industry is Lee's Pharmaceutical Holdings in?
Lee's Pharmaceutical Holdings’s primary industry is Pharmaceuticals.
-
Is Lee's Pharmaceutical Holdings a private or public company?
Lee's Pharmaceutical Holdings is a Public company.
-
What is Lee's Pharmaceutical Holdings’s stock symbol?
The ticker symbol for Lee's Pharmaceutical Holdings is 00950.
-
What is the current stock price of Lee's Pharmaceutical Holdings?
As of 13-Nov-2026 the stock price of Lee's Pharmaceutical Holdings is $0.13.
-
What is the current market cap of Lee's Pharmaceutical Holdings?
The current market capitalization of Lee's Pharmaceutical Holdings is $78.8M.
-
What is Lee's Pharmaceutical Holdings’s current revenue?
The trailing twelve month revenue for Lee's Pharmaceutical Holdings is $197M.
-
What is Lee's Pharmaceutical Holdings’s annual earnings per share (EPS)?
Lee's Pharmaceutical Holdings’s EPS for 12 months was $0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process